Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05561738 · ClinicalTrials.gov registry record · NA
Nicotinamide Riboside in Ulcerative Colitis
A NA study of Ulcerative Colitis, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05561738: Recruiting NA study of Ulcerative Colitis, sponsored by University of Pittsburgh.
NCT05561738 is a NA study of Ulcerative Colitis that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 40 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05561738, a NA study of Ulcerative Colitis, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
Primary Outcome
The investigators will report the number of overall patients screened for enrollment.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- OTHER Standard of Care
- DIETARY_SUPPLEMENT Nicotinamide Riboside Chloride
Study Locations (1)
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-02-28 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05561738 shows while recruiting
NCT05561738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05561738 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05561738 about?
NCT05561738 is a clinical study titled "Nicotinamide Riboside in Ulcerative Colitis". This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
What is the current status of trial NCT05561738?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-02-28. Estimated completion is 2026-06-30.
What conditions does trial NCT05561738 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT05561738?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Standard of Care (OTHER), Nicotinamide Riboside Chloride (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05561738?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05561738 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05561738's enrollment target sits among peer trials
40 94th of 122 higher than 28 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
RECRUITING · NA
-
Fermented Food-Supplemented Diet in Ulcerative Colitis
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
RECRUITING · NA
-
BOOM-IBD2 Pivotal Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI